RecruitingNot ApplicableNCT06020209

CCT for Comprehensive Risk Stratification Following STEMI

Cardiac Computed Tomography for Comprehensive Risk Stratification of Arrhythmic, Atherothrombotic and Heart Failure Events Following Reperfused ST-segment Elevation Myocardial Infarction

Sponsor

University of Turin, Italy

Enrollment

200 participants

Start Date

Nov 8, 2023

Study Type

INTERVENTIONAL

Conditions

Myocardial Infarction

Summary

The CT-STEMI study aims to evaluate a comprehensive cardiac computed tomography (CCT) protocol for assessing the risk of heart failure (HF), life-threatening arrhythmias (LTA), and atherothrombotic events following ST-elevation myocardial infarction (STEMI). This multicenter, prospective study has three main objectives: 1. Comparing the diagnostic accuracy of the comprehensive CCT protocol with cardiac magnetic resonance (CMR), considered the non-invasive gold standard. 2. Determining the prognostic value of CCT in assessing myocardial tissue adverse features related to STEMI. 3. Evaluating the atherosclerotic burden in patients with post-acute STEMI. Two hundred patients will undergo both CCT and CMR in the post-acute phase, and their follow-up will focus on monitoring HF, LTA, and ischemic events. The CT-STEMI study represents the first attempt to assess the potential of CCT in providing a comprehensive risk assessment following STEMI in a large contemporary population. The findings of this study have the potential to revolutionize post-STEMI risk stratification practices.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether a specialized CT scan (cardiac CT) done after a heart attack treated with emergency stenting can better assess the extent of heart damage and predict future risk, compared to MRI alone. **You may be eligible if...** - You have been diagnosed with a STEMI (a major type of heart attack) and received emergency stenting within 24 hours of symptoms - You are hemodynamically stable (no need for medications to support blood pressure) within 4 days of the event **You may NOT be eligible if...** - You have known severe kidney disease (GFR under 30) - You have a known allergy to CT or MRI contrast agents - You are unable or unwilling to undergo CT or MRI - You are pregnant or breastfeeding - You have severe heart valve disease or uncontrolled severe arrhythmias - You had pre-existing heart failure symptoms before this event Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCardiac Computed Tomography

A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.

DIAGNOSTIC_TESTCardiac Magnetic Resonance

A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.